I-Mab (NASDAQ:IMAB – Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,170,000 shares, a growth of 7.3% from the March 15th total of 1,090,000 shares. Based on an average daily volume of 436,300 shares, the days-to-cover ratio is presently 2.7 days.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on IMAB shares. Piper Sandler dropped their price target on shares of I-Mab from $15.00 to $10.00 and set an “overweight” rating on the stock in a research note on Monday, March 18th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target (down previously from $18.00) on shares of I-Mab in a research note on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of I-Mab in a report on Friday, January 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of I-Mab in a report on Friday, April 12th.
View Our Latest Stock Report on IMAB
Institutional Trading of I-Mab
I-Mab Stock Down 0.6 %
Shares of NASDAQ:IMAB opened at $1.79 on Wednesday. The firm has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $1.68. I-Mab has a fifty-two week low of $1.16 and a fifty-two week high of $3.76.
I-Mab Company Profile
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.
Recommended Stories
- Five stocks we like better than I-Mab
- Want to Profit on the Downtrend? Downtrends, Explained.
- ASML Fires Warning Shot For Tech Investors
- How to Calculate Options Profits
- Prologis Stock Leading U.S. Logistics Boom
- ESG Stocks, What Investors Should Know
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.